Interpace Biosciences IncOTCQX US:IDXG
- LAST PRICE1.0300
- TODAY'S CHANGE (%)-0.1000 (-8.8496%)
- Bid / Lots1.0300/ 1
- Ask / Lots1.1000/ 10
- Open / Previous Close1.0475 / 1.1300
- Day Range
- 52 Week Range
- Volume2,580
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IDXG |
|---|---|---|
| 09:57 ET | 1900 | 1.03 |
| 10:33 ET | 600 | 1.03 |
Nov 8, 2023
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results, from 3:29PM ET on Wednesday Nov 08, 2023 by Dow Jones
3:29PM ET on Wednesday Nov 08, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Interpace Biosciences Inc | 4.9M | -4.0x | --- |
Alignment Healthcare Inc | 1.4B | -8.8x | --- |
Progyny Inc | 3.3B | 66.2x | --- |
Clover Health Investments Corp | 459.2M | -2.0x | --- |
Molina Healthcare Inc | 21.4B | 22.8x | --- |
Humana Inc | 62.9B | 21.3x | +4.49% |
Company Information
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The Company, through its Interpace Diagnostics, provides clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, which is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, which is a molecular version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT, which is for the diagnosis of thyroid cancer from thyroid nodules utilizing a sequencing assay; ThyraMIR v2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer, and RespriDX, which differentiates lung cancer of primary versus metastatic origin.
Contact Information
- Headquarters
- Waterview Plaza Suite 310, 2001 Route 46PARSIPPANY, NJ, United States 07054
- Phone
- 412-224-6100
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Robert Gorman
- President, Chief Executive Officer, Director
- Thomas Burnell
- Chief Financial Officer
- Christopher Mccarthy
- Independent Director
- Vijay Aggarwal
- Independent Director
- Joseph Keegan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.9M |
|---|---|
Revenue (TTM) | $38.3M |
Shares Outstanding | 4.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-0.26 |
Book Value | $-3.85 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | 24.7x |
Operating Margin | 4.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
